

Akums gets DCGI approval for triple combination diabetes treatment

26 July 2023 | News

Sitagliptin 100, Pioglitazone 15 and Metformin 1000/500 is specifically formulated for the treatment of diabetes

New Delhi-based contract development and manufacturing organisation Akums Drugs and Pharmaceuticals has secured approval from the Drug Controller General of India (DCGI) for its groundbreaking triple combination diabetes treatment. Sitagliptin 100, Pioglitazone 15 and Metformin 1000/500 comes as a more advanced treatment for diabetes, with much more efficacy and precision than monotherapy drugs that are currently in the market.

Sitagliptin 100, Pioglitazone 15 and Metformin 1000/500 is specifically formulated for the treatment of diabetes and offers a number of pharmacological advantages. The combination contains three distinctly active formulations such as Metformin, a glucose-lowering agent often prescribed as a first-line therapy for Type-2 diabetes (T2D).

Pioglitazone, on the other hand, is an outstanding component as it is considered effective against T2D because of its ability to improve insulin sensitivity, lower HbA1c levels, and promote lipid metabolism and insulin secretion. The third component in the combination is Sitagliptin, which has been observed to significantly reduce HbA(1c) levels when used as an add-on therapy after the administration of insulin, sulfonylureas, or thiazolidinediones, or alone with or without metformin.

"We have carefully studied the pharmacological properties of these formulations and with Sitagliptin 100, Pioglitazone 15 and Metamorfine 1000/500, we found the right blend for our triple-active combination. This is going to better serve anti-diabetic patients who require better treatment without necessarily swallowing multiple drugs," said Sanjeev Jain, Jt. Managing Director, Akums Drugs & Pharmaceuticals.